Search results for "ORPHAN DRUG|Designated/Withdrawn|Treatment of primary biliary cirrhosis" in comments (approximate match)
Showing 1 - 2 of 2 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Maralixibat (Livmarli™) is a potent, apical, sodium‐dependent, bile acid transporter competitive inhibitor with minimal systemic absorption being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagil...